Nasdaq

Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference

SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, ...
Nasdaq

Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, ...
The American Journal of Managed Care

FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1-Positive NSCLC

Repotrectinib achieved a high objective response rate and durable response in the pivotal TRIDENT-1 trial. Repotrectinib is an orally administered tyrosine kinase inhibitor (TKI) that targets ROS1 ...
Business Wire

TP Therapeutics Announces Updated Interim Phase 1 Data with Repotrectinib (TPX-0005) in ROS1 Fusion-positive NSCLC to be Presented at World Conference on Lung Cancer

SAN DIEGO--(BUSINESS WIRE)--TP Therapeutics, a privately held, clinical-stage biopharmaceutical company developing oncology therapies with a focus on addressing drug resistance, announced today that ...
Finanznachrichten

Trident 1 + Smartwaiver: A Smarter, Safer, and More Efficient Way to Run Your Range

Trident 1 Announces Strategic Partnership with Smartwaiver to Streamline Waiver Management and Improve Range Operations HOUSTON, TEXAS / ACCESS Newswire / August 18, 2025 / Trident 1, the leading ...
Business Wire

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 Study

SAN DIEGO--(BUSINESS WIRE)--TP Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing oncology therapies with a focus on addressing current drug resistance, today ...